Comparison · NCT06597084-sae
Group A vs Group B: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: serious adverse events. Trial comparisons, record NCT06597084-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06597084-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.197 | 0.116 | 0.313 | wilson | |
| Risk in group 2 | 0.21 | 0.127 | 0.326 | wilson | |
| Risk difference, group 1 minus group 2 | -0.013 | -0.155 | 0.13 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.938 | 0.466 | 1.89 | log | |
| Odds ratio, group 1 over group 2 | 0.923 | 0.383 | 2.22 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Group A than on Group B | 77.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | ESL 800 mg~ESL 800 mg: 800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line. | 12 | 61 | EG000 |
| Group 2 | Group B | Placebo~Placebo: Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line. | 13 | 62 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
The period of monitored/assessed for the collection of AEs started with the first onset or worsening after the first investigational medicinal product (IMP) intake at V1b until 14 days after the last IMP intake, up to 18 months per participant.
Source ClinicalTrials.gov
Trial
- Title
- Anti-epileptogenic Effects of Eslicarbazepine Acetate
- NCT number
- NCT06597084
- Phases
- PHASE2
- Conditions
- Post Stroke Epilepsy
- Interventions
- ESL 800 mg, Placebo
- Lead sponsor
- Bial - Portela C S.A.
- Results first posted
- 2025-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06597084?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06597084-sae